JP6761852B2 - がん治療 - Google Patents
がん治療 Download PDFInfo
- Publication number
- JP6761852B2 JP6761852B2 JP2018511527A JP2018511527A JP6761852B2 JP 6761852 B2 JP6761852 B2 JP 6761852B2 JP 2018511527 A JP2018511527 A JP 2018511527A JP 2018511527 A JP2018511527 A JP 2018511527A JP 6761852 B2 JP6761852 B2 JP 6761852B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- nuc
- treatment
- patient
- cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/051438 WO2016181093A1 (en) | 2015-05-14 | 2015-05-14 | Cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019040537A Division JP6810763B2 (ja) | 2019-03-06 | 2019-03-06 | がん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515618A JP2018515618A (ja) | 2018-06-14 |
| JP2018515618A5 JP2018515618A5 (cg-RX-API-DMAC7.html) | 2018-07-26 |
| JP6761852B2 true JP6761852B2 (ja) | 2020-09-30 |
Family
ID=53276184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511527A Expired - Fee Related JP6761852B2 (ja) | 2015-05-14 | 2015-05-14 | がん治療 |
Country Status (26)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| DK3031812T3 (en) | 2011-03-01 | 2018-09-17 | NuCana plc | CHEMICAL COMPOUNDS |
| SI3150616T1 (sl) | 2012-11-16 | 2017-08-31 | University College Cardiff Consultants Limited | Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata |
| WO2015198059A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Formulation comprising a gemcitabine-prodrug |
| EP3160978B1 (en) | 2014-06-25 | 2020-07-29 | NuCana plc | Gemcitabine prodrugs |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| LT3224268T (lt) | 2014-11-28 | 2019-09-25 | NuCana plc | Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai |
| BR112018003594A2 (pt) | 2015-09-25 | 2018-09-25 | Hoffmann La Roche | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados |
| PH12018500691B1 (en) | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
| RS62593B1 (sr) | 2015-12-11 | 2021-12-31 | NuCana plc | Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031 |
| HUE050290T2 (hu) * | 2015-12-23 | 2020-11-30 | NuCana plc | Kombinált terápia |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| CA3008769A1 (en) * | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| EP3863674A2 (en) | 2018-10-12 | 2021-08-18 | The Regents of the University of Colorado, a body corporate | Compositions and methods for reducing cancer stem cells |
| CN117462555B (zh) * | 2021-01-31 | 2025-12-30 | 兰州大学 | 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
-
2015
- 2015-05-14 SM SM20180303T patent/SMT201800303T1/it unknown
- 2015-05-14 US US15/573,969 patent/US20180289733A1/en not_active Abandoned
- 2015-05-14 CN CN202310013004.2A patent/CN115837028A/zh not_active Withdrawn
- 2015-05-14 HU HUE15726258A patent/HUE038541T2/hu unknown
- 2015-05-14 MX MX2020009154A patent/MX390506B/es unknown
- 2015-05-14 ES ES15726258.5T patent/ES2668377T3/es active Active
- 2015-05-14 WO PCT/GB2015/051438 patent/WO2016181093A1/en not_active Ceased
- 2015-05-14 KR KR1020177035629A patent/KR20180021697A/ko not_active Ceased
- 2015-05-14 EP EP15726258.5A patent/EP3197456B2/en active Active
- 2015-05-14 JP JP2018511527A patent/JP6761852B2/ja not_active Expired - Fee Related
- 2015-05-14 HR HRP20180762TT patent/HRP20180762T1/hr unknown
- 2015-05-14 PT PT157262585T patent/PT3197456T/pt unknown
- 2015-05-14 TR TR2018/06642T patent/TR201806642T4/tr unknown
- 2015-05-14 CN CN201580081668.6A patent/CN107835687A/zh active Pending
- 2015-05-14 CA CA2985540A patent/CA2985540C/en active Active
- 2015-05-14 RS RS20180575A patent/RS57371B1/sr unknown
- 2015-05-14 LT LTEP15726258.5T patent/LT3197456T/lt unknown
- 2015-05-14 EA EA201792509A patent/EA201792509A1/ru unknown
- 2015-05-14 MX MX2017014544A patent/MX374946B/es active IP Right Grant
- 2015-05-14 EP EP18164408.9A patent/EP3415149A1/en not_active Withdrawn
- 2015-05-14 PH PH1/2017/502086A patent/PH12017502086B1/en unknown
- 2015-05-14 AU AU2015394135A patent/AU2015394135B2/en not_active Ceased
- 2015-05-14 DK DK15726258.5T patent/DK3197456T3/en active
- 2015-05-14 MY MYPI2017001657A patent/MY192081A/en unknown
- 2015-05-14 SI SI201530240T patent/SI3197456T1/en unknown
- 2015-05-14 PL PL15726258T patent/PL3197456T3/pl unknown
- 2015-05-14 BR BR112017024461-6A patent/BR112017024461B1/pt not_active IP Right Cessation
-
2017
- 2017-11-12 IL IL255591A patent/IL255591B/en unknown
-
2018
- 2018-05-18 CY CY20181100519T patent/CY1120516T1/el unknown
-
2020
- 2020-09-22 US US17/028,314 patent/US20210100825A1/en not_active Abandoned
-
2021
- 2021-11-30 AU AU2021277614A patent/AU2021277614A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,472 patent/US20230226092A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6761852B2 (ja) | がん治療 | |
| JP7367910B2 (ja) | がんの処置 | |
| MX2014010591A (es) | Terapia combinada para el tratamiento de cancer de ovario. | |
| JP2024527087A (ja) | スピロノラクトン及びアシルフルベンの組み合わせによるがんの処置 | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| JP6810763B2 (ja) | がん治療 | |
| HK1261423A1 (en) | Cancer treatments | |
| EA040796B1 (ru) | Лечение рака | |
| HK1237283B (en) | Cancer treatments | |
| HK1237283A1 (en) | Cancer treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180511 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180511 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180511 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200716 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200907 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6761852 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |